106 related articles for article (PubMed ID: 26944246)
1. Lowering the High Cost of Cancer Drugs--III.
Attaran A; Mackey T; Beall R
Mayo Clin Proc; 2016 Mar; 91(3):399-400. PubMed ID: 26944246
[No Abstract] [Full Text] [Related]
2. Lowering the High Cost of Cancer Drugs--I.
Braillon A
Mayo Clin Proc; 2016 Mar; 91(3):397. PubMed ID: 26944245
[No Abstract] [Full Text] [Related]
3. In Reply--Lowering the High Cost of Cancer Drugs.
Kantarjian H; Tefferi A
Mayo Clin Proc; 2016 Mar; 91(3):401-3. PubMed ID: 26944248
[No Abstract] [Full Text] [Related]
4. Lowering the High Cost of Cancer Drugs--IV.
Martenson JA
Mayo Clin Proc; 2016 Mar; 91(3):400-1. PubMed ID: 26944247
[No Abstract] [Full Text] [Related]
5. US oncologists call for government regulation to curb drug price rises.
McCarthy M
BMJ; 2015 Jul; 351():h4063. PubMed ID: 26208848
[No Abstract] [Full Text] [Related]
6. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Tefferi A; Kantarjian H; Rajkumar SV; Baker LH; Abkowitz JL; Adamson JW; Advani RH; Allison J; Antman KH; Bast RC; Bennett JM; Benz EJ; Berliner N; Bertino J; Bhatia R; Bhatia S; Bhojwani D; Blanke CD; Bloomfield CD; Bosserman L; Broxmeyer HE; Byrd JC; Cabanillas F; Canellos GP; Chabner BA; Chanan-Khan A; Cheson B; Clarkson B; Cohn SL; Colon-Otero G; Cortes J; Coutre S; Cristofanilli M; Curran WJ; Daley GQ; DeAngelo DJ; Deeg HJ; Einhorn LH; Erba HP; Esteva FJ; Estey E; Fidler IJ; Foran J; Forman S; Freireich E; Fuchs C; George JN; Gertz MA; Giralt S; Golomb H; Greenberg P; Gutterman J; Handin RI; Hellman S; Hoff PM; Hoffman R; Hong WK; Horowitz M; Hortobagyi GN; Hudis C; Issa JP; Johnson BE; Kantoff PW; Kaushansky K; Khayat D; Khuri FR; Kipps TJ; Kripke M; Kyle RA; Larson RA; Lawrence TS; Levine R; Link MP; Lippman SM; Lonial S; Lyman GH; Markman M; Mendelsohn J; Meropol NJ; Messinger Y; Mulvey TM; O'Brien S; Perez-Soler R; Pollock R; Prchal J; Press O; Radich J; Rai K; Rosenberg SA; Rowe JM; Rugo H; Runowicz CD; Sandmaier BM; Saven A; Schafer AI; Schiffer C; Sekeres MA; Silver RT; Siu LL; Steensma DP; Stewart FM; Stock W; Stone R; Storb R; Strong LC; Tallman MS; Thompson M; Ueno NT; Van Etten RA; Vose JM; Wiernik PH; Winer EP; Younes A; Zelenetz AD; LeMaistre CA
Mayo Clin Proc; 2015 Aug; 90(8):996-1000. PubMed ID: 26211600
[No Abstract] [Full Text] [Related]
7. Overspending driven by oversized single dose vials of cancer drugs.
Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
[No Abstract] [Full Text] [Related]
8. Oncology drug pricing structure is broken.
Hutchinson L
Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
[No Abstract] [Full Text] [Related]
9. Medicare cost containment strategy targets several oncology drugs.
Twombly R
J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
[No Abstract] [Full Text] [Related]
10. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
11. News feature: Costly US anticancer drugs pose problems for doctors and patients.
Charatan F
BMJ; 2008 Jul; 337(7662):a778. PubMed ID: 18625596
[TBL] [Abstract][Full Text] [Related]
12. Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs.
Bekelman JE; Joffe S
JAMA; 2018 Jun; 319(21):2167-2168. PubMed ID: 29710240
[No Abstract] [Full Text] [Related]
13. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
14. [Pharmacoeconomic aspects of oral cytostatic agents].
Poquet Jornet JE; Carrera-Hueso FJ; Gasent Blesa JM; Peris Godoy M
Farm Hosp; 2011 May; 35 Suppl 2():25-31. PubMed ID: 22445506
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches to delivering value in oncology drugs.
Miller S
Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
[No Abstract] [Full Text] [Related]
16. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
American Society of Clinical Oncology
J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
[No Abstract] [Full Text] [Related]
17. Drugs for cancer and copayments.
Finlay I; Crisp N
BMJ; 2008 Jun; 337(7660):a527. PubMed ID: 18595953
[TBL] [Abstract][Full Text] [Related]
18. Japanese Cancer Association Meeting UICC International session--what is cost-effectiveness in cancer treatment?
Akaza H; Kawahara N; Roh JK; Inoue H; Park EC; Lee KS; Kim S; Hayre J; Naidoo B; Wilkinson T; Fukuda T; Jang WI; Nogimori M
Asian Pac J Cancer Prev; 2014; 15(1):3-10. PubMed ID: 24528045
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness and cancer drugs.
Battley JE; Connell LC; Graham DM; O'Reilly S
J Clin Oncol; 2014 Apr; 32(10):1091-2. PubMed ID: 24590642
[No Abstract] [Full Text] [Related]
20. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
